Hexagon Nutrition operates as an integrated nutrition manufacturer formulating micronutrient premixes, therapeutic foods, and clinical nutrition products for global B2B and B2C customers. The business spans three core segments: high-margin branded consumer nutrition, premixes, and tender-based ESG foods. In FY26, the premix segment contributed 35% to 40% of revenue, while the branded and ESG segments each contributed 30%. Exports constituted 57% of total revenue, with over 80% of export revenue derived from premixes and ESG foods. The company competes globally against large MNCs like DSM, BASF, and Nestle, yet its margin profile reveals a resilient converter model. Blended EBITDA margin improved to 13.83% in FY26 from 12.33% in FY25, with PAT margin expanding to 9.9% from 7.5%. This margin level indicates average to good business quality, but the true economic engine is the branded segment, which commands 60% to 68% margins and drives the overall profit trajectory.
The economics of this business persist through specialized formulation barriers and product differentiation rather than scale alone. In the clinical nutrition and premix markets, the company achieves differentiation through complex formulations, such as products featuring three to four protein blends with distinct amino acid profiles. This technical complexity creates switching costs for B2B customers and establishes pricing power in the branded consumer segment, allowing the company to pass raw material price increases directly to consumers via MRP hikes. However, the premix and ESG segments operate in a more commoditized environment dominated by global MNCs. The ESG segment, which relies on UN and government tenders, generates margins of 25% to 30% and is subject to cyclical working capital fluctuations, as evidenced by trade receivables expanding to INR82 crores during large Q3 and Q4 FY26 dispatches before normalizing.
The inflection over the next 18 to 24 months centers on mix shift and operating leverage rather than greenfield capacity addition. Management expects blended capacity utilization to range around 35% to 40% going forward, with the branded business currently operating at 50% to 60% utilization and the premix business at 40% to 45%. The trigger for accelerated earnings is the deliberate expansion of sales teams and distribution networks into Tier 2 and Tier 3 cities, alongside increased e-commerce penetration through platforms like Amazon and Flipkart. By 18 to 24 months out, the company targets doubling revenue over a 3 to 5 year horizon, supported by the rapid scaling of pediatric and weight management branded products. As the high-margin branded volume grows, overall EBITDA margins will expand further from the FY26 level of 13.83%, driven by improved product mix and manufacturing efficiencies.
Management's walk-talk demonstrates consistent execution on margin improvement and operational scaling. Over the last four years, the company doubled its EBITDA margin from 6.2% to 13.83% in FY26, primarily driven by branded business volume growth contributing over 50% gross margin. On the July 2026 call, management committed to maintaining the revenue growth momentum achieved over the last two to three years and expects operating leverage to drive further margin expansion. Capital allocation remains focused on organic expansion of sales infrastructure rather than dilution or debt-funded acquisitions. The balance sheet absorbed working capital pressure during large ESG dispatches, with trade receivables rising from INR60 crores to INR82 crores, but management confirmed normalization has occurred, indicating disciplined receivables management.
Earnings visibility hinges on the continued mix shift toward the 60% to 68% margin branded segment, which must grow faster than the overall business to lift blended EBITDA toward the 15% to 18% range over the next 18 to 24 months. For this trajectory to hold, the company must successfully penetrate Tier 2 and Tier 3 cities while expanding e-commerce and e-pharmacy channels for its pediatric and weight management brands. The single most important watchpoint is raw material supply security, as less than 25% of critical inputs like Vitamin A, B-group, C, and folic acid are imported from China, Singapore, Korea, and Europe. Any sustained supply chain disruption or geopolitical escalation in West Asia, which accounts for less than 20% of exports, could compress premix and ESG margins if input costs spike and cannot be passed through. The structural tension between working capital tied up in ESG tenders and the cash-generating branded segment must resolve toward branded dominance for the operating leverage thesis to fully materialize.
companyname: Hexagon Nutrition Limited ticker: HEXAGON sector: Nutrition / Food Ingredients / Healthcare Hexagon Nutrition Limited is an integrated nutrition company that blends vitamins and minerals into premixes for food manufacturers, makes therapeutic foods for malnutrition programs, and sells its own branded clinical nutrition products. The company was founded in 1993 and listed on the NSE and BSE in FY26. It operates two manufacturing plants in India (Nashik, Maharashtra and Chennai, Tami...
Read the full report →Get valuation models, detailed research reports, thematic primers, one-pagers, risk analysis, growth triggers, bear case, capex tracker, walk the talk, and more for Hexagon Nutrition Limited and 4,900+ companies.
5-day free pass. No card required.